Close Menu

Amgen

A Phase II study comparing front-line treatment with anti-EGFR drug Vectibix against anti-VEGF therapy Avastin in a genetically defined subset of metastatic colorectal cancer patients has yielded promising results in favor of the anti-EGFR agent.

In BMC Genomics, Swiss researchers described efforts to sequence and characterize the genome of a previously unknown Gram-negative bacterial species from a family called Alcal

NEW YORK (GenomeWeb News) – Alliance Global today said that it has signed an agreement with Amgen to provide cancer mutation testing in certain countries in the Middle East and Africa.

NEW YORK (GenomeWeb News) – Dako today announced a project with Amgen to develop a companion diagnostic test using Dako's IQFISH hybridization buffer.

NEW YORK (GenomeWeb News) – Illumina and Amgen will collaborate on the development of a next-generation sequencing-based companion diagnostic for the colorectal cancer drug Vectibix (panitumumab), the companies announced yesterday.

NEW YORK (GenomeWeb News) – Massachusetts General Hospital, the Broad Institute, and Amgen are collaborating to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease, the partners said today.

NEW YORK (GenomeWeb News) – In Nature Genetics, an international team led by investigators at the University of Michigan, the Broad Institute, and Massachusetts General Hospital presented a computa

NEW YORK (GenomeWeb News) – Nextcode Health officially launched today, saying it has licensed technology developed by Decode Genetics that it will use to accelerate the diagnosis of cancer through sequencing-based data.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.